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Abstract 
Transglutaminases are confounding enzymes which are known to play key roles in various 
cellular processes. In this paper, we aim to bring together several pieces of evidence from 
published research and literature that suggest a potentially vital role for transglutaminases in 
receptor tyrosine kinases (RTK) signalling. We cite literature that confirm and suggest the 
formation of integrin:RTK:transglutaminase complexes and explore the occurrence and 
functionality of these complexes in a large fraction of the RTK family. 
 
Transglutaminases 
Transglutaminases (TGases) are a family of structurally and functionally related Ca2+-
dependent enzymes that catalyse the formation of -glutamyl isopeptide bonds in proteins by 
transamidation of specific glutamine residues (Lorand and Graham. 2003). In addition to their 
role in protein cross-linking, TGases are also known to catalyse deamidation, amine 
incorporation, esterification and phosphorylation of particular substrates and the slow 
hydrolysis of previously formed isopeptide bonds; elaborated in (Lorand and Graham. 2003). 
Although the broader physiological roles of TGases still remain unclear, their ability to cross-
link extracellular matrix (ECM) proteins such as fibronectin (FN) (LeMosy et al. 1992), 
vitronectin (VN) (Sane et al. 1988), several collagens (Bowness et al. 1987; Kleman et al. 
1995), laminin-nidogen complexes (Aeschlimann and Paulsson. 1991) and osteopontin 
(Kaartinen et al. 1997) are very well documented. 
TG2 or tissue TG, the most carefully studied member of the family, is found and is active in 
both the cytoplasmic and extracellular space (Fesus and Piacentini. 2002). It associates with a 
wide range of integrins in both contexts: forming 1:1 complexes with the extracellular 
domain of the 1, 3 and 5 integrin subunits (Akimov et al. 2000; Zemskov et al. 2006), 
and binding the GFFKR sequence in the IIb, 5 and v integrins (Kang et al. 2004), a motif 
that is strictly conserved in 13 of the 18 human  integrin subunits. Integrins are a family of 
heterodimeric transmembrane adhesion receptors that mediate cell-ECM adhesion by 
simultaneously binding ECM proteins outside the cell, clustering, and establishing linkage to 
the actin cytoskeleton inside the cell (Bokel and Brown. 2002). TG2 has been shown to bind 
51 integrin and FN via two distinct domains which, subsequently allows the formation of 
ternary complexes in the ECM, including TG2-FN-integrin (Akimov and Belkin. 2001; 
Akimov et al. 2000).  
Integrins and receptor tyrosine kinases 
Integrins have been found to play an important part in mediating cell-signalling events by 
regulating the binding of growth factors or cytokines to growth factor receptors, including a 
large number of RTKs (Legate et al. 2009). RTKs are a large family of single-pass 
transmembrane receptors wherein the binding of their respective ligands promotes the 
autophosphorylation of their cytoplasmic domains and initiates subsequent events that play 
key roles in most metazoan cellular processes (Robinson et al. 2000).  Receptors from this 
family are of key interest in the investigation of phenomena such as developmental processes  
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(Holder and Klein. 1999), stem cell growth and differentiation (Arai et al. 2004), tissue 
maintenance and wound healing (Upton et al. 2008), diabetes (Robinson et al. 2000) and the 
pathogenesis, drug resistance and metastasis of cancers (Hollier et al. 2008; Kashyap et al. 
2011; Samani et al. 2007). Activities of several RTKs have been demonstrated to be 
modulated by ligand binding to integrins (Somanath et al. 2009). Ligand occupancy of 
integrin receptors triggers integrin clustering and its association with the cytoskeleton. The 
close association between integrins and growth factor receptor complexes, demonstrated as 
clustering of RTKs within a few hundred nanometres of the integrins, has been most recently 
and comprehensively demonstrated using a new technique dubbed Enzyme-Mediated 
Activation of Radical Source (EMARS) (Kotani et al. 2008). The αvβ3 integrin has been 
reported to directly associate with several RTK family members, such as the platelet-derived 
growth factor receptor (PDGFR) (Schneller et al. 1997), vascular endothelial growth factor 
receptor (VEGFR) (Somanath et al. 2009), and the insulin-like growth factor-I receptor 
(IGF1R) (Clemmons and Maile. 2005). Similarly, the epidermal growth factor receptor 
(EGFR) has been shown to directly associate with αvβ1 and αvβ4 integrins (Falcioni et al. 
1997). The association between integrins and growth factor receptors can lead to partial 
activation of the growth factor receptor, subsequently leading to faster downstream responses 
on ligand occupancy (Moro et al. 1998). Taking into consideration that RTKs cluster around 
the same integrins that TGs bind, it is possible that integrin-bound TGs affect RTKs and their 
signalling processes.  
Established direct TG:integrin:RTK associations 
The first evidence of a direct TG-mediated interaction between an RTK and an integrin came 
from the observation that factor XIIIa  activates the VEGFR2 in a growth factor-independent 
fashion by cross-linking the receptor to the v3 integrin and enhancing vascular endothelial 
cell migration, proliferation and survival (Dardik et al. 2005).  In a follow-up study (Dardik 
and Inbal. 2006) it was demonstrated that cytoplasmic TG2 also interacts with VEGFR-2, 
mediating VEGF-stimulated translocation of the receptor to the cell nucleus and down 
regulating the migratory effects of the growth factor. This establishes the underlying fact that 
there is close association between the TGases and VEGFR.  
The two platelet-derived growth factor receptors, PDGFR and - are close relatives of the 
VEGFR family, and share a similar extracellular domain structure. It is perhaps not surprising 
then, that a recent study demonstrated an association between PDGFR and -, TG2 and the 
1 integrin (Zemskov et al. 2009). TG2 binds the extracellular portion of either PDGFR or -
, stimulating clustering of receptors with the 1 integrins and enhancing receptor turnover, 
mitosis and migration (Zemskov et al. 2009).  
An earlier study (Schneller et al. 1997) indicated that the PDGFR also interacts with the 
v3 integrin where ligand-dependent co-immunoprecipitation of v3 and a highly-
phosphorylated sub-fraction of PDGFR- was observed.  Moreover, the effects of PDGF on 
downstream signalling were significantly enhanced when cells were plated on the v3 
ligand VN, rather than on the non-v3 ligand collagen I. Whether TGases play a role in the 
PDGFR-v3 interaction is an open question; given the parallels with the VEGFR2 it seems 
reasonable to consider that an interaction between PDGFR and the v3 integrin is indeed 
plausible. 
RTKs for which RTK-integrin and RTK-TG interactions have been separately 
established 
Cross-talk between the EGFR and various TG2-binding integrins, in both an EGF-
independent (Moro et al. 1998) and EGF-dependent (Ricono et al. 2009) fashion, is a well-
established phenomenon.  Interactions between TG2 and EGFR are similarly yet separately 
well-established.  Depending on circumstances, stimulation of EGFR may inhibit (Antonyak 
et al. 2003) or enhance (Antonyak et al. 2004) TG2 expression.  Similarly, TG2 has been 
documented to influence EGF signalling (Maruko et al. 2009; Toth et al. 2009); research 
demonstrating TG2’s inhibitory effect on EGF signalling has additionally established that the 
extracellular domain of EGFR is a TG2 substrate (Maruko et al. 2009). 
Members of the Ephs, the largest family of RTKs, display both positive and negative 
interactions with integrins under various circumstances (Alford et al. 2007).  The ligands for 
these receptors, the ephrins, exist variously as transmembrane or soluble proteins.  Soluble 
ephrin A1 and A5 are cross-linked into oligomers by TG2 in vitro; these complexes stimulate 
enhanced activation of EphA1 and –A4 compared to the monomeric species (Alford et al. 
2007). 
It has been conclusively demonstrated by our group and others that the IGF1R cooperates 
with certain integrins in its signalling (Doerr and Jones. 1996; Goel et al. 2005; Hollier et al. 
2008; Kricker et al. 2003; Maile et al. 2006; Upton et al. 2008; Van Lonkhuyzen et al. 2007).  
IGF1R is known to colocalize with 1 integrins (Kiely et al. 2006; Kotani et al. 2008). Our 
research has shown that noncovalent complexes of vitronectin, IGF binding proteins 
(IGFBPs) and IGF-I, or vitronectin-IGF-I chimeric analogues, can stimulate cell migration to 
a far greater extent than vitronectin or IGF-I alone (Hollier et al. 2008; Kricker et al. 2003; 
Van Lonkhuyzen et al. 2007). This strongly suggests that the same is true of the vitronectin-
binding v1, -3 and -5 integrins.  Direct insulin-dependent interaction of IR and IRS-1 
(Insulin Receptor Substrate 1) with the v3 integrin has also been demonstrated (Schneller 
et al. 1997; Vuori and Ruoslahti. 1994).  That these integrins are known to associate with 
TG2 at the cell surface (Fesus and Piacentini. 2002) is certainly suggestive of the formation 
of a similar integrin:TG:receptor complex as has been observed for the VEGFR2 and 
PDGFR. 
Tying it all together: ECM proteins present RTK ligands to integrin-bound TG2 
As mentioned earlier, a substantial amount of work by our laboratory and others has 
demonstrated that VN, which binds EGF, bFGF, IGF-II and, via the IGFBPs, IGF-I, potently 
enhances the signalling of these growth factors compared to their free form via co-activation 
of their RTKs, VN- and the TG2-binding integrins such as v1, 3 and 5 (Doerr and 
Jones. 1996; Goel et al. 2005; Hollier et al. 2008; Kricker et al. 2003; Maile et al. 2006; 
Upton et al. 2008; Van Lonkhuyzen et al. 2007).  Such complexes, when bound to the 
integrin, bring the complexed growth factor into direct proximity to the integrin. The tertiary 
structure of FN is relatively well resolved compared to VN and it has been recently shown 
that the 12th-14th type III domains of FN form an extremely promiscuous growth factor 
binding region, binding most members of the PDGF, VEGF and bFGF families as well as 
(via IGFBPs) IGF-I, but not EGF (Martino and Hubbell. 2010).  It can also be readily shown 
via existing crystal structures that when FN is bound to the integrin via its RGD sequence, the 
growth factor binding region must lie directly adjacent to the TG2-binding  integrin (Figure 
1).  Once we consider all documented pairwise associations between integrins, TG2, FN (or 
VN), growth factors and RTKs, association of a growth factor thus bound with its cognate 
RTK is theoretically capable of bringing both intra- and extracellular domains of the RTK 




A relationship between RTKs, integrins and TGases may be common to the entire RTK 
family 
Direct, ternary association between RTKs, integrins and TGases has thus been demonstrated 
for three members of the RTK family, while circumstantial evidence in the form of 
colocalisation with integrins and separate functional interactions with integrins and TGases 
exists for at least four more.  It is instructive to consider the relationship between these 
receptors in the context of the RTK family tree (constructed according to the methods of 
(Robinson et al. 2000)) (Figure 2).  If we consider only those receptors for which a 
RTK:TG:integrin complex has been definitively demonstrated, the number of implicated 
receptors is rather small (those highlighted in green).  If, however, we consider the more 
general criteria of separate, documented interactions with TGase and the TG2-binding 
integrins, the last common ancestor of the RTKs discussed in this review is in fact the last 
common ancestor of all but two of the human RTKs.  We suggest that all members of the 












Given the current state of knowledge, expanding interest towards discovery of the 
relationship between RTKs and TGases will enable us to improve our understanding of the 
pattern of TG-mediated interactions under various conditions, and how this is disrupted in 
disease states. In keeping with this, TGases have been demonstrated to play key roles in a 
surprising array of apparently unrelated diseases, the most serious of which are cancers 
(Mehta et al. 2010), intracellular plaque-related neurodegenerative disorders (Jeitner et al. 
2009) and autoimmune diseases (Dieterich et al. 2006).  
Here we have outlined how increasing evidence directs to how TGases and RTKs work 
together and this in turn raises possibilities of how this could act as a fundamental mediator 
of the eukaryotic signalling and trafficking system.   
Figure legends: 
Figure 1: FN, a key ECM protein, binds TG2, integrins, and a wide range of RTK-binding 
growth factors.  (a) Schematic of the FN domain structure, highlighting key binding sites.  FN 
binds TG2 within the 6-domain collagen binding region near its N-terminus, while integrin 
and growth factor binding sites are clustered near the C-terminus of the protein.  (b) Binding 
to the 51 integrin brings the growth factor binding region into juxtaposition with the 1  
integrin and hence, presumably, integrin-bound TG2.  The large distance from the TG2 
binding region suggests that TG2 binds a second FN chain, consistent with its role in FN 
fibrillogenesis; this has been omitted for clarity.  An additional TG2 molecule may be found 
in complex with the GFFKR motif on the cytoplasmic tail of the alpha integrin.  (c) Binding 
of an RTK to a FN-bound growth factor thus presented, necessarily brings both extra- and 
intracellular domains of the RTK into close proximity with integrin-bound TG2. 
Figure 2:  A phylogenetic tree of the RTK family (adapted from (Robinson et al. 2000)) and 
annotated to indicate current knowledge regarding their associations with TGs.  Each RTK is 
labelled with its UniProt accession number and gene name. * = Separate, documented 
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